JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking at the…
All articles by Eve Thomas
Eve Thomas
Eve Thomas is a reporter writing across a variety of sectors with a specific focus on thematic intelligence. She has a BA in English Literature from the University of Sheffield and an MSt in English from Oxford University.
-
-
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg…
-
Broader population could benefit from Novartis spinal muscular atrophy treatment
Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA) gene transfer therapy –…
-
Insilico announces positive results from Phase I trials of AI-designed ISM5411
Hong Kong-based Insilico Medicine has announced positive results from two Phase I studies of ISM5411 (NCT06012578), a novel gut-restricted and…
-
Study finds restrictive clinical trial criteria excludes Lyme disease patients
New analysis of real-world data from the largest US Lyme disease registry, MyLymeData, has shown that most persistent Lyme disease…
-
Percheron plans to broaden pipeline following avicursen disappointment
Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing…
-
The Christie reports promise in bladder cancer therapy trial
Early signals from an ongoing study at the Christie Hospital in Manchester shore up the evidence for an investigational treatment…
-
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery…
-
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity…
-
First patient dosed as Marengo’s invikafusp alfa trial expands to Europe
Clinical-stage biotechnology company Marengo Therapeutics has announced that it has dosed the first patient in Phase II of its STARt-001…